Press release 5 March 2007 BioGaia signs new agreement with Semper BioGaia AB has signed an agreement with Semper AB which gives Semper the rights to add Lactobacillus reuteri in gruel products in the Nordic markets. BioGaia´s patented probiotic, Lactobacillus reuteri, balances the gut flora in children and has been shown in clinical trials to have strong positive effects. A study performed by Professor Weizman in Israel that was published in the medical journal Pediatrics shows that Lactobacillus reuteri given to small children protected them from infections and gave: - lower absence from day school due to sickness - fewer visits to the doctor - reduced need for antibiotics Semper is Sweden´s leading baby food company, with a market share of approx. 60 %. Semper has over 50 years experience of developing and marketing good and nutritionally adapted products for small children. “Gruel with health-promoting bacteria is an excellent complement to our existing products” says Agneta Frykhammar, Marketing Director of Semper AB. “We have several customers in a series of countries that add Lactobacillus reuteri to products adapted to the needs of small children. It is satisfying that we ca now, together with Semper, also offer Swedish children a gruel with health-promoting and friendly bacteria.” says Peter Rothschild, MD BioGaia AB. Launch of Semper´s “ Fullkornsvälling” with active bacteria culture is planned during the first half of 2007. Latest press releases from BioGaia: 2007-02-21 BioGaia signs agreement with Delta Medical 2007-02-14 BioGaia AB Year-end report 2006 2007-01-16 BioGaia signs agreement with Semper For additional information contact: Peter Rothschild, president, telephone: +46 (0)8 - 555 293 00 Jan Annwall, executive vice president, telephone: +46 (0)8 - 555 293 00 -------------------------------------------------------------------------------- ----------------------------------------------------------- BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the small cap list of the Stockholm Stock Exchange. www.biogaia.com